

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort Scientific Corporation

微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

**DISCLOSEABLE TRANSACTION
SUPPLEMENTAL AGREEMENTS IN RELATION TO THE PROPOSED
RESTRUCTURING AND
DEEMED DISPOSAL OF INTERESTS IN
MICROPORT CARDIOFLOW MEDTECH**

Reference is made to the announcements of MicroPort Scientific Corporation (the “**Company**”) dated 22 March 2019 and 27 March 2019 (together, the “**Announcements**”) in relation to the proposed restructuring and deemed disposal of interests in MP CardioFlow. Unless the context otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

Shareholders and investors should refer to the Announcements for details of the Restructuring.

On 29 October 2019, the parties to the share purchase agreement dated 22 March 2019 (the “**Share Purchase Agreement**”) entered to a supplemental agreement to reduce the number of preferred shares of the Target Company to be subscribed by Qianyi Investment I L.P. (the “**Series C Investor**”) under the Series C Investment from 12,500,000 Series C Shares to 11,250,000 Series C Shares (the “**Adjusted Series C Investment**”). The purchase price for the Series C Shares has also been correspondingly reduced from US\$50,000,000 to US\$45,000,000 (the “**Adjusted Series C Purchase Price**”).

As a result of the Adjusted Series C Investment, the shareholding structure of the Target Company upon completion of the Restructuring and the Series C Investment will be as follows:

Shareholder	% shareholding in the Target Company under the original terms of the Restructuring and Series C Investment	% shareholding in the Target Company upon completion of the Restructuring and the Adjusted Series C Investment
Controlling Shareholder	56.6257%	57.3425%
Chenxue Entity	6.6619%	6.7462%
Shanghai Huahao	9.5841%	9.7054%
CICC Kangrui	9.0796%	9.1945%
Huatai Ruihe	3.0265%	3.0649%
SDIC Chuanghe	2.5222%	2.5541%
Series C Investor	12.5000%	11.3924%
Total	100.0000%	100.0000%

The Target Company indirectly holds the entire equity interest in MP CardioFlow.

As of the date of this announcement, the Target Company has already received from the Series C Investor the Adjusted Series C Purchase Price of US\$45,000,000. The Directors do not expect the Adjusted Series C Investment and the Adjusted Series C Purchase Price will have any material adverse effect on the operation and financial position of MP CardioFlow.

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 29 October 2019

As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive Directors are Mr. Norihiro Ashida, Mr. Hiroshi Shirafuji and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only*